Oryzon Genomics Overview
- Year Founded
-
2000
- Status
-
Public
- Employees
-
44
- Stock Symbol
-
ORY
- Investments
-
1
- Share Price
-
$2.59
- (As of Friday Closing)
Oryzon Genomics General Information
Description
Oryzon Genomics SA is a clinical stage biopharmaceutical company and engaged in the development of epigenetics-based therapeutics. It is engaged in the field of epigenetic medicine and in the development of therapeutic, biological solutions for cancer and neurodegenerative diseases.
Contact Information
Website
www.oryzon.comCorporate Office
- Carrer de Sant Ferran 74
- Cornellà de Llobregat
- 08940 Barcelona
- Spain
Corporate Office
- Carrer de Sant Ferran 74
- Cornellà de Llobregat
- 08940 Barcelona
- Spain
Oryzon Genomics Timeline
Oryzon Genomics Stock Performance
As of 13-Nov-2026, Oryzon Genomics’s stock price is $2.59. Its current market cap is $212M with 82M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $2.59 | $2.86 | $2.55 - $4.14 | $212M | 82M | 191K | -$0.03 |
Oryzon Genomics Financials Summary
As of 30-Jun-2026, Oryzon Genomics has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 273,674 | 288,056 | 92,644 | 128,405 |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (7,901) | (6,282) | (4,667) | (4,427) |
| Net Income | (2,381) | (2,939) | (3,872) | (3,628) |
| Total Assets | 160,564 | 169,761 | 114,303 | 118,167 |
| Total Debt | 6,655 | 8,968 | 11,658 | 15,130 |
Oryzon Genomics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Oryzon Genomics Comparisons
Industry
Financing
Details
Oryzon Genomics Competitors (45)
One of Oryzon Genomics’s 45 competitors is Passage Bio, a Formerly VC-backed company based in Philadelphia, PA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Passage Bio | Formerly VC-backed | Philadelphia, PA | ||||
| Capricor Therapeutics | Formerly VC-backed | San Diego, CA | ||||
| Sarepta Therapeutics | Formerly VC-backed | Cambridge, MA | ||||
| aTyr Pharma | Formerly VC-backed | San Diego, CA | ||||
| Sharp Therapeutics (Biotechnology) | Formerly VC-backed | Pittsburgh, PA |
Oryzon Genomics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Oryzon Genomics Patents
Oryzon Genomics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2023385514-A1 | Combinations of lsd1 inhibitors and menin inhibitors for treating cancer | Pending | 24-Nov-2022 | ||
| EP-4622635-A1 | Combinations of lsd1 inhibitors and menin inhibitors for treating cancer | Pending | 24-Nov-2022 | ||
| US-20260151399-A1 | Combinations of lsd1 inhibitors and menin inhibitors for treating cancer | Pending | 24-Nov-2022 | ||
| WO-2024110649-A1 | Combinations of lsd1 inhibitors and menin inhibitors for treating cancer | Inactive | 24-Nov-2022 | ||
| EP-4522136-A1 | Methods of treating malignant peripheral nerve sheath tumor (mpnst) using lsd1 inhibitors | Pending | 09-May-2022 | A61K31/506 |
Oryzon Genomics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Oryzon Genomics Acquisitions (1)
Oryzon Genomics’s most recent deal was a Merger/Acquisition with Crystax. The deal was made on 27-Jan-2009.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Crystax | 27-Jan-2009 | Merger/Acquisition | Biotechnology |
Oryzon Genomics ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
34.54 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,592
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
Oryzon Genomics FAQs
-
When was Oryzon Genomics founded?
Oryzon Genomics was founded in 2000.
-
Where is Oryzon Genomics headquartered?
Oryzon Genomics is headquartered in Barcelona, Spain.
-
What is the size of Oryzon Genomics?
Oryzon Genomics has 44 total employees.
-
What industry is Oryzon Genomics in?
Oryzon Genomics’s primary industry is Drug Discovery.
-
Is Oryzon Genomics a private or public company?
Oryzon Genomics is a Public company.
-
What is Oryzon Genomics’s stock symbol?
The ticker symbol for Oryzon Genomics is ORY.
-
What is the current stock price of Oryzon Genomics?
As of 13-Nov-2026 the stock price of Oryzon Genomics is $2.59.
-
What is the current market cap of Oryzon Genomics?
The current market capitalization of Oryzon Genomics is $212M.
-
Who are Oryzon Genomics’s competitors?
Passage Bio, Capricor Therapeutics, Sarepta Therapeutics, aTyr Pharma, and Sharp Therapeutics (Biotechnology) are some of the 45 competitors of Oryzon Genomics.
-
What is Oryzon Genomics’s annual earnings per share (EPS)?
Oryzon Genomics’s EPS for 12 months was -$0.03.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
